CommercialCoverageMedium impact
06.02.47f, Noninvasive Prenatal Screening for Fetal Aneuploidies Using Cell-Free Fetal DNA (Independence Administrators)
Independence Blue Cross·OB-GYN·Medical Policy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators has updated policy 06.02.47f effective January 1, 2025, establishing coverage guidelines for noninvasive prenatal screening (NIPS) using cell-free fetal DNA testing for fetal aneuploidies. Billing teams must review the full policy text to identify specific coverage criteria, prior authorization requirements, and applicable billing codes to ensure compliant claim submission.
Action Required
By February 28, 2025: Billing team and providers must obtain and review the complete policy text at the source URL (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=01&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-06-02-47f). Identify: (1) specific CPT/HCPCS codes for NIPS testing covered under this policy, (2) prior authorization requirements and submission process, (3) medical necessity criteria for fetal aneuploidy screening. Update billing system rules, encounter forms, and provider education materials accordingly. Ensure all NIPS claims submitted on or after 01/01/2025 comply with updated guidelines. Claims submitted without adherence to new requirements may be denied.